References
1. McCarthy BJ, Shibui S, Kayama T, et al. Primary CNS germ cell tumors in Japan and the United States: An analysis of 4 tumor registries.Neuro Oncol . 2012;14(9):1194-1200.
2. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol . 2016;131(6):803-820.
3. Kong Z, Wang Y, Dai C, Yao Y, Ma W, Wang Y. Central Nervous System Germ Cell Tumors: A Review of the Literature. J Child Neurol . 2018;33(9):610-620.
4. Matsutani M, Sano K, Takakura K, et al. Primary intracranial germ cell tumors: A clinical analysis of 153 histologically verified cases.J Neurosurg . 1997;86(3):446-455.
5. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol . 2017;19(12):1661-1672.
6. Calaminus G, Kortmann R, Worch J, et al. SIOP CNS GCT 96: Final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease.Neuro Oncol . 2013;15(6):788-796.
7. Ogawa K, Shikama N, Toita T, et al. Long-term results of radiotherapy for intracranial germinoma: A multi-institutional retrospective review of 126 patients. Int J Radiat Oncol Biol Phys . 2004;58(3):705-713.
8. Modak S, Gardner S, Dunkel IJ, et al. Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors. J Clin Oncol . 2004;22(10):1934-1943.
9. Bouffet E, Baranzelli MC, Patte C, et al. Combined treatment modality for intracranial germinomas: Results of a multicentre SFOP experience.Br J Cancer . 1999;79(7-8):1199-1204.
10. da Silva NS, Cappellano AM, Diez B, et al. Primary chemotherapy for intracranial germ cell tumors: Results of the third international CNS germ cell tumor study. Pediatr Blood Cancer . 2010;54(3):377-383.
11. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. Int J Cancer . 2017;141(3):621-635. doi:10.1002/ijc.30755
12. Bouffet E. The role of myeloablative chemotherapy with autologous hematopoietic cell rescue in central nervous system germ cell tumors.Pediatr Blood Cancer . 2010;54(4):644-646.
13. Callec L, Lardy-Cleaud A, Guerrini-Rousseau L, et al. Relapsing intracranial germ cell tumours warrant retreatment. Eur J Cancer . 2020;136:186-194.
14. EA E, P T, J B, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer . 2009;45(2):228-247.
15. Murray MJ, Bailey S, Heinemann K, et al. Treatment and outcomes of UK and German patients with relapsed intracranial germ cell tumors following uniform first-line therapy. Int J Cancer . 2017;141(3):621-635.
16. Murray MJ, Bartels U, Nishikawa R, Fangusaro J, Matsutani M, Nicholson JC. Consensus on the management of intracranial germ-cell tumours. Lancet Oncol . 2015;16(9):e470-e477.
17. Calaminus G, Frappaz D, Kortmann RD, et al. Outcome of patients with intracranial non-germinomatous germ cell tumors—lessons from the SIOP-CNS-GCT-96 trial. Neuro Oncol . 2017;19(12):1661-1672.
18. Wilson S. GUIDANCE FOR THE MANAGEMENT OF PATIENTS WITH RELAPSED INTRACRANIAL GERM CELL TUMOURS AFTER INITIAL PRIMARY TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY On Behalf of the CCLG Germ Cell Tumour Special Interest Group-Guidance Lead Guidance Author .; 2021.